SMT201600380B - Formulazioni di darunavir - Google Patents

Formulazioni di darunavir

Info

Publication number
SMT201600380B
SMT201600380B SM201600380T SM201600380T SMT201600380B SM T201600380 B SMT201600380 B SM T201600380B SM 201600380 T SM201600380 T SM 201600380T SM 201600380 T SM201600380 T SM 201600380T SM T201600380 B SMT201600380 B SM T201600380B
Authority
SM
San Marino
Prior art keywords
darunavir
formulations
Prior art date
Application number
SM201600380T
Other languages
English (en)
Italian (it)
Inventor
Urbain Alfons C Delaet
Philip Erna H Heyns
Eugeen Maria Jozef Jans
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of SMT201600380B publication Critical patent/SMT201600380B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SM201600380T 2011-07-07 2016-10-26 Formulazioni di darunavir SMT201600380B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11173066 2011-07-07

Publications (1)

Publication Number Publication Date
SMT201600380B true SMT201600380B (it) 2017-01-10

Family

ID=46458539

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600380T SMT201600380B (it) 2011-07-07 2016-10-26 Formulazioni di darunavir

Country Status (23)

Country Link
US (3) US20140142174A1 (enExample)
EP (1) EP2729128B1 (enExample)
JP (1) JP6101260B2 (enExample)
KR (1) KR101817991B1 (enExample)
CN (1) CN103841962B (enExample)
AU (1) AU2012280277B2 (enExample)
BR (1) BR112014000195A2 (enExample)
CA (1) CA2837539C (enExample)
CY (1) CY1119446T1 (enExample)
DK (1) DK2729128T3 (enExample)
EA (1) EA026588B1 (enExample)
ES (1) ES2598823T3 (enExample)
HR (1) HRP20161340T1 (enExample)
HU (1) HUE030341T2 (enExample)
IL (1) IL229700B (enExample)
LT (1) LT2729128T (enExample)
MX (1) MX341976B (enExample)
PL (1) PL2729128T3 (enExample)
PT (1) PT2729128T (enExample)
RS (1) RS55236B1 (enExample)
SI (1) SI2729128T1 (enExample)
SM (1) SMT201600380B (enExample)
WO (1) WO2013004816A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2729130T (pt) 2011-07-07 2017-12-13 Gilead Sciences Inc Formulações de combinação de darunavir
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨,替诺福韦,达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
JP5843986B2 (ja) * 2014-03-25 2016-01-13 アステラス製薬株式会社 粒状医薬組成物
WO2015155673A1 (en) 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
EP3210017B1 (en) 2014-10-26 2021-10-06 King Abdullah University Of Science And Technology Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (hiv)
BR112020000842A2 (pt) 2017-07-20 2020-07-21 Janssen Sciences Ireland Unlimited Company composições e métodos para tratamento do hiv
US20200101093A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of Treating and Preventing Neuropsychiatric and/or Neurocognitive Complications in Patients Infected with HIV
US20210290590A1 (en) 2020-03-13 2021-09-23 Janssen Sciences Ireland Unlimited Company Methods of treating subjects infected with hiv
US11311559B2 (en) * 2020-04-20 2022-04-26 Poviva Corp. Compositions and methods for enhanced delivery of antiviral agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
WO1995006030A1 (en) 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
AU771780B2 (en) 1998-06-23 2004-04-01 Board Of Trustees Of The University Of Illinois, The Fitness assay and associated methods
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
RU2010102067A (ru) * 2007-06-25 2011-07-27 Тиботек Фармасьютикалз (Ie) Комбинированные композиции, включающие дарунавир и этравирин
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
PT2477992T (pt) * 2009-09-17 2017-03-20 Mylan Laboratories Ltd Processos para a preparação de darunavir e a forma amorfa do mesmo

Also Published As

Publication number Publication date
CA2837539C (en) 2021-08-10
US20140142174A1 (en) 2014-05-22
PT2729128T (pt) 2016-09-21
IL229700A0 (en) 2014-01-30
US20210244749A1 (en) 2021-08-12
BR112014000195A2 (pt) 2017-02-21
EA201490223A1 (ru) 2014-06-30
EP2729128B1 (en) 2016-07-27
US20160113949A1 (en) 2016-04-28
ES2598823T3 (es) 2017-01-30
EA026588B1 (ru) 2017-04-28
SI2729128T1 (sl) 2016-11-30
RS55236B1 (sr) 2017-02-28
MX2013015196A (es) 2014-08-18
HRP20161340T1 (hr) 2016-12-02
CN103841962A (zh) 2014-06-04
KR101817991B1 (ko) 2018-01-12
IL229700B (en) 2018-04-30
CN103841962B (zh) 2016-08-17
LT2729128T (lt) 2016-11-10
JP2014520786A (ja) 2014-08-25
WO2013004816A1 (en) 2013-01-10
KR20140068844A (ko) 2014-06-09
DK2729128T3 (en) 2016-11-21
CY1119446T1 (el) 2018-04-04
AU2012280277A1 (en) 2013-12-19
MX341976B (es) 2016-09-07
AU2012280277B2 (en) 2017-02-09
EP2729128A1 (en) 2014-05-14
JP6101260B2 (ja) 2017-03-22
HUE030341T2 (en) 2017-05-29
PL2729128T3 (pl) 2017-05-31
CA2837539A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
SMT201700094B (it) Composto di pirazina carbossammide
EP2736491A4 (en) BEPOTASTIN COMPOSITION
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
SMT201900181T1 (it) Metodi di preparazione di coniugati
EP2713762A4 (en) Stevia-COMPOSITION
ZA201501847B (en) Formulations of enzalutamide
SMT201600464B (it) Procedimento per la preparazione di esterolo
EP2706981A4 (en) COSMETIC COMPOSITIONS
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
SMT201600153B (it) Derivato di azolo
SMT201600380B (it) Formulazioni di darunavir
CO6900117A2 (es) Formulaciones peptídicas de liberación controlada
BR112014003878A2 (pt) síntese de r-bifenilalaninol
HRP20171889T1 (hr) Formulacije kombinacije darunavira
CO6940426A2 (es) Formulaciones farmacéuticas
BR112014000015A2 (pt) formulação
CO6791617A2 (es) Combinaciones de compuestos activos
EP2691361A4 (en) SYNTHESIS OF DIAZIDEN
EP2931042A4 (en) ANTHRACYCLINFORMULIERUNGEN
EP2770828A4 (en) FORMULATION
DK2672817T3 (da) Forbedrede insekticide formuleringer
BR112013031545A2 (pt) composições cosméticas
DK2407155T3 (da) Formuleringer af inecalcitol
HRP20180587T1 (hr) Pripravak krutog surfaktanta